NGL Fine-Chem LimitedNGLFINECorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Mar 2026 13 quarters of data

₹2,784.60

MCap ₹1,720 Cr · P/E 41.7

NGL Fine-Chem Limited — Stock analysis & AI research NGL Fine-Chem Limited — Multibagger AI analysis NGL Fine-Chem Limited — Seasonality — best & worst months NGL Fine-Chem Limited — Technical indicators & charts NGL Fine-Chem Limited — Technical setup — score, trend, support & resistance NGL Fine-Chem Limited — Live exchange announcements

📋 High Interest Coverage Stocks 📋 High Profit Growth Stocks 📋 Stocks With Strong Quarterly Results 📋 GARP Stocks (PEG Below 1)📋 High Promoter Holding Stocks 📋 Quality Stocks 📈 MACD Bearish Crossover 📈 Accumulation (OBV Rising) 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹145 Cr

Sales · Mar 2026

+55.9% YoY

₹18 Cr

Operating Profit · Mar 2026

+350.0% YoY

12.4%

OPM % · Mar 2026

+188.4% YoY

₹11 Cr

Net Profit · Mar 2026

+1200.0% YoY

₹18.37

EPS · Mar 2026

+2286.9% YoY

📝 NGL Fine-Chem Limited — results explained

Quarter ended March 2026 (Q4 FY26)

NGL Fine-Chem Limited reported revenue of ₹145 crore for the quarter ended March 2026 (Q4 FY26), up 55.9% from ₹93 crore in the same quarter last year, and up 14.8% sequentially over the December 2025 quarter.

The company swung to a net profit of ₹11 crore from a net loss of ₹1 crore a year earlier. Earnings per share (EPS) came in at ₹18.37.

Operating profit stood at ₹18 crore — an operating margin (OPM) of 12.4%, compared with 4.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, NGL Fine-Chem Limited posted revenue of ₹489 crore, a growth of 36.1% over FY25, with a net profit of ₹41 crore (up 133.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹489 crore with a net profit of ₹41 crore.

Valuation snapshot

At the current price of ₹2,784.60, NGLFINE has a market capitalisation of ₹1,720 crore and a trailing P/E of about 41.7.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the 5th-largest of the 11 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 72.49%, foreign institutional investors (FIIs) 0.05%, domestic institutional investors (DIIs) 0.02%, public shareholders 27.43% of NGL Fine-Chem Limited.

Promoter holding slipped from 72.73% to 72.49% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹1,720 Cr

Current Price ?

₹2,784.6

P/E ?

41.68above ind

Industry P/E ?

32.10

P/B ?

5.38

P/S ?

3.52

P/FCF ?

-33.73

Enterprise Value ?

₹1,828 Cr

EV/EBITDA ?

30.69

PEG ?

1.54

Earnings Yield ?

2.4%

Dividend Yield ?

0.06%

Profitability & Returns

Sales (TTM) ?

₹489 Cr

OPM ?

12.2%

Profit after tax (TTM) ?

₹41 Cr

EPS (TTM) ?

₹66.81

ROCE ?

15.0%

ROE ?

12.9%

ROA ?

7.8%

Growth

Sales — latest qtr ?

₹145 Cr

PAT — latest qtr ?

₹11 Cr

YoY qtr sales growth ?

55.9%

YoY qtr profit growth ?

1,200.0%

Sales growth (3y) ?

21%

Sales growth (5y) ?

14%

Profit growth (3y) ?

27%

Profit growth (5y) ?

-6%

Financial Health

Debt ?

₹108 Cr

Debt to Equity ?

0.34

Interest Coverage ?

9.8

Current Ratio ?

N/A

Ownership

Promoter holding ?

72.49%

Change in promoter holding ?

-0.25%

Pledged percentage ?

N/A

Market

Return 3 months ?

-11.1%

Return 6 months ?

25.1%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	YoY %	QoQ %
Sales	73	69	79	85	96	88	91	87	93	101	117	126	145	+55.9%	+14.8%
Operating Profit	11	8	13	11	13	6	11	4	4	8	14	20	18	+350.0%	-10.4%
Other Income	3	4	4	4	4	6	5	0	-1	7	2	5	3	+400.0%	-36.0%
Interest	0	0	0	0	0	0	0	1	1	1	1	1	1	+0.0%	-5.3%
Depreciation	2	2	2	2	2	2	2	2	3	3	4	4	4	+33.3%	-8.0%
Profit Before Tax	11	9	15	13	14	10	13	1	0	10	11	19	15	—	-22.6%
Net Profit	9	8	11	9	11	8	10	1	-1	8	8	15	11	+1200.0%	-25.4%
EPS	13.81	12.63	17.76	14.40	17.56	12.67	16.26	1.27	-0.84	12.37	12.78	23.85	18.37	+2286.9%	-23.0%
OPM %	14.6%	11.0%	16.5%	12.9%	13.2%	7.2%	11.6%	4.1%	4.3%	7.7%	11.7%	15.9%	12.4%	+188.4%	-22.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹359 Cr	₹489 Cr	₹489 Cr	+36.1%
Operating Profit	₹25 Cr	₹60 Cr	₹60 Cr	+143.1%
OPM %	6.82%	12.18%	12.18%	+78.6%
NPM %	4.91%	8.44%	8.44%	+71.9%
Other Income	₹11 Cr	₹17 Cr	₹17 Cr	+53.5%
Depreciation	₹10 Cr	₹16 Cr	₹16 Cr	+64.8%
Interest	₹2 Cr	₹4 Cr	₹4 Cr	+87.4%
EBIT	₹15 Cr	₹44 Cr	₹44 Cr	+194.9%
PBT	₹24 Cr	₹55 Cr	₹55 Cr	+125.8%
Tax	₹-1 Cr	₹9 Cr	₹9 Cr	+865.1%
Net Profit	₹18 Cr	₹41 Cr	₹41 Cr	+133.8%
EPS	₹29.36	₹67.37	₹67.37	+129.5%
Material Cost	₹132 Cr	₹183 Cr	₹183 Cr	+38.3%
Employee Cost	₹38 Cr	₹45 Cr	₹45 Cr	+18.0%
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	3	3	3	3	+0.0%
Reserves	222	260	277	317	+14.4%
Borrowings	32	34	76	108	+42.1%
Other Liabilities	30	56	70	102	+45.7%
Total Liabilities	288	353	426	530	+24.4%
Fixed Assets	59	60	120	144	+20.0%
CWIP	26	46	50	95	+90.0%
Investments	43	57	63	43	-31.7%
Other Assets	159	190	193	248	+28.5%
Total Assets	288	353	426	530	+24.4%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	32	11	17	35	+105.9%
Cash from Investing Activity	-24	-17	-16	-65	-306.2%
Cash from Financing Activity	-1	-1	-1	30	+3100.0%
Net Cash Flow	7	-7	0	0	—
Free Cash Flow	3	-17	-56	-51	+8.9%
CFO/OP	134%	52%	86%	79%	-8.1%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	86	92	81	94	+16.0%
Inventory Days	69	99	95	102	+7.4%
Days Payable	59	110	105	90	-14.3%
Cash Conversion Cycle	97	82	71	106	+49.3%
Working Capital Days	67	71	51	88	+72.5%
ROCE %	12%	19%	8%	15%	+87.5%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	% Chg
Promoters	72.74%	72.74%	72.74%	72.73%	72.49%	-0.3%
FIIs	0.00%	0.00%	0.00%	0.03%	0.05%	+66.7%
DIIs	0.00%	0.00%	0.00%	0.00%	0.02%	—
Public	27.26%	27.26%	27.26%	27.23%	27.43%	+0.7%
No. of Shareholders	14,010	13,387	12,834	12,516	13,393	+7.0%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SMSPHARMA SMS Pharmaceuticals	₹442.45	4,144	39.7	898	102	19.3%	11.4%	13.3%	48.6%	5.6%	-1.4%
2	AARTIDRUGS Aarti Drugs	₹428.30	3,909	20.5	2,678	191	12.4%	7.1%	7.5%	16.3%	18.9%	-7.2%
3	HIKAL Hikal	₹229.83	2,834	—	1,734	-34	13.4%	-2.0%	-8.0%	-154.4%	6.0%	67.0%
4	BETA Beta Drugs	₹2,064.90	2,084	37.5	513	57	20.5%	11.2%	—	—	25.5%	31.7%
5	NGLFINE NGL Fine-Chem	₹2,786.60	1,722	30.1	536	57	15.6%	10.6%	36.0%	123.2%	33.6%	99.1%
6	ANUHPHR Anuh Pharma	₹92.99	932	21.1	779	44	8.6%	5.7%	16.5%	-12.8%	4.2%	42.8%
7	INFINIUM Infinium Pharma	₹222.95	347	31.2	190	14	11.3%	7.2%	—	—	45.2%	166.7%
8	AAREYDRUGS Aarey Drugs	₹98.71	329	67.1	415	4	1.6%	1.0%	-0.4%	12.3%	-56.3%	-25.3%
9	PAR Par Drugs	₹128.90	159	10.9	109	14	18.3%	13.3%	2.7%	-1.9%	20.1%	41.6%
10	KREBSBIO Krebs Biochemicals	₹57.94	125	—	25	-14	-10.0%	-55.9%	-45.2%	37.1%	27.4%	53.3%
11	VILINBIO Vilin Bio	₹18.00	27	14.2	42	2	7.6%	4.6%	—	—	215.9%	1680.0%

❓ Frequently asked questions

What was NGL Fine-Chem Limited's revenue in Q4 FY26?

What was NGL Fine-Chem Limited's net profit in Q4 FY26?